JP2020513032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513032A5 JP2020513032A5 JP2020502532A JP2020502532A JP2020513032A5 JP 2020513032 A5 JP2020513032 A5 JP 2020513032A5 JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020513032 A5 JP2020513032 A5 JP 2020513032A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- sequestering
- metabolite
- behavioral symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480039P | 2017-03-31 | 2017-03-31 | |
| US62/480,039 | 2017-03-31 | ||
| PCT/US2018/025607 WO2018183986A1 (en) | 2017-03-31 | 2018-03-31 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513032A JP2020513032A (ja) | 2020-04-30 |
| JP2020513032A5 true JP2020513032A5 (enExample) | 2021-04-15 |
| JP6978122B2 JP6978122B2 (ja) | 2021-12-08 |
Family
ID=63677186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502532A Expired - Fee Related JP6978122B2 (ja) | 2017-03-31 | 2018-03-31 | 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10617718B2 (enExample) |
| EP (1) | EP3600349A4 (enExample) |
| JP (1) | JP6978122B2 (enExample) |
| KR (1) | KR102328323B1 (enExample) |
| CN (2) | CN114569633B (enExample) |
| AU (3) | AU2018243836B9 (enExample) |
| BR (1) | BR112019020289A2 (enExample) |
| CA (2) | CA3095724C (enExample) |
| WO (1) | WO2018183986A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095724C (en) | 2017-03-31 | 2023-04-18 | Axial Biotherapeutics, Inc. | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| WO2021011481A1 (en) * | 2019-07-12 | 2021-01-21 | The General Hospital Corporation | Anti-inflammatory factors |
| CN114829629A (zh) * | 2019-12-19 | 2022-07-29 | 希尔氏宠物营养品公司 | 治疗和降低患上与犬科动物的升高的4-乙基苯基硫酸盐相关的病状的风险的组合物和方法以及鉴定有风险患上此类病状的犬科动物的方法 |
| US20240197795A1 (en) * | 2020-07-27 | 2024-06-20 | Boadie DUNLOP | Assessment and treatment of depression, anxiety, or related disorders |
| CN113440522B (zh) * | 2021-07-29 | 2022-12-13 | 中山大学附属第七医院(深圳) | 一种吲哚丙酸在制备用于治疗自闭症药物中的应用 |
| CN115825314A (zh) * | 2021-09-17 | 2023-03-21 | 中国科学院深圳先进技术研究院 | 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用 |
| WO2023154966A1 (en) * | 2022-02-14 | 2023-08-17 | Axial Therapeutics, Inc. | Compositions and methods for sequestering metabolites in the gastrointestinal tract |
| WO2023154547A1 (en) | 2022-02-14 | 2023-08-17 | Axial Therapeutics, Inc. | Colon targeted drug delivery |
| CN116990395A (zh) * | 2022-04-26 | 2023-11-03 | 中国科学院深圳先进技术研究院 | 一种基于粪便的阿尔兹海默症生物标志物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761284A (en) * | 1977-12-27 | 1988-08-02 | Kureha Kagaku Kogy Kabushiki Kaisha | Antidote including activated carbon particles |
| JPS5673542A (en) * | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
| GB9611437D0 (en) | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| CA2588567A1 (en) | 2004-12-13 | 2006-06-22 | Arena Pharmaceuticals, Inc. | N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| US20120046273A1 (en) | 2009-03-05 | 2012-02-23 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| JP5701971B2 (ja) * | 2011-03-04 | 2015-04-15 | 株式会社クレハ | 錠剤型の経口投与用組成物及びその製造方法 |
| WO2012161921A1 (en) * | 2011-05-23 | 2012-11-29 | Thomas Jefferson University | Intestinal hyperpermeability and prevention of systemic disease |
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
| CN114949001A (zh) * | 2012-08-29 | 2022-08-30 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| TWI520751B (zh) | 2013-02-22 | 2016-02-11 | 吳羽股份有限公司 | 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑 |
| EP3019624B1 (en) | 2013-07-09 | 2020-09-16 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
| EP3024461B1 (en) * | 2013-07-23 | 2020-05-13 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| US20150111878A1 (en) * | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US9763903B2 (en) * | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| WO2015150590A1 (en) * | 2014-04-04 | 2015-10-08 | Biotechnobel Sa | Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract |
| CA3095724C (en) | 2017-03-31 | 2023-04-18 | Axial Biotherapeutics, Inc. | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
-
2018
- 2018-03-31 CA CA3095724A patent/CA3095724C/en active Active
- 2018-03-31 KR KR1020197032302A patent/KR102328323B1/ko not_active Expired - Fee Related
- 2018-03-31 CA CA3191747A patent/CA3191747A1/en active Pending
- 2018-03-31 CN CN202210138407.5A patent/CN114569633B/zh not_active Expired - Fee Related
- 2018-03-31 BR BR112019020289-7A patent/BR112019020289A2/pt not_active Application Discontinuation
- 2018-03-31 AU AU2018243836A patent/AU2018243836B9/en not_active Ceased
- 2018-03-31 JP JP2020502532A patent/JP6978122B2/ja not_active Expired - Fee Related
- 2018-03-31 CN CN201880034095.5A patent/CN110944650B/zh not_active Expired - Fee Related
- 2018-03-31 WO PCT/US2018/025607 patent/WO2018183986A1/en not_active Ceased
- 2018-03-31 EP EP18778222.2A patent/EP3600349A4/en not_active Withdrawn
- 2018-05-31 US US15/994,571 patent/US10617718B2/en active Active
-
2020
- 2020-03-23 US US16/827,629 patent/US20200390809A1/en not_active Abandoned
- 2020-06-10 US US16/898,201 patent/US11007219B2/en not_active Expired - Fee Related
-
2021
- 2021-07-22 AU AU2021206871A patent/AU2021206871B2/en not_active Ceased
-
2022
- 2022-01-14 AU AU2022200220A patent/AU2022200220A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/345,279 patent/US20230364135A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513032A5 (enExample) | ||
| Eckert et al. | Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold | |
| JP2018513107A5 (enExample) | ||
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| JP2014518275A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2011520911A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| CN109310769A (zh) | 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗 | |
| WO2019235577A1 (ja) | 酸化ストレスに起因する疾患の予防又は治療剤 | |
| RU2018113272A (ru) | Никотиновые составы и способы их получения и применения | |
| JP7090731B2 (ja) | 柿葉抽出物及びその製剤の新規医薬用途 | |
| JP2018529747A5 (enExample) | ||
| JP2019503335A (ja) | ジメチルアミノミケリオリドの使用 | |
| Mollica et al. | Obstructive sleep apnea and cardiovascular risks in the elderly population | |
| JP4180258B2 (ja) | ＩｇＥ抗体抑制剤および食品 | |
| CN105496992A (zh) | 氨溴索沙丁胺醇脂质固体分散体 | |
| CN104161742A (zh) | 芬戈莫德及其结构类似物用于制备治疗脑出血药物的应用 | |
| CN105078899B (zh) | 一种恩诺沙星复层高分子矫味骨架微粒及其制备方法 | |
| CN105456201B (zh) | 氨溴索沙丁胺醇微丸的制备方法 | |
| RU2278670C2 (ru) | Способ лечения бронхиальной астмы у детей в период ремиссии | |
| JP2021525796A (ja) | 神経疾患の阻害 | |
| RU2347576C1 (ru) | Средство для коррекции гиперреактивности дыхательных путей у детей | |
| CN110152003B (zh) | 一种用于治疗copd的复方药物及其制备方法 | |
| Simeó et al. | PO: 04: 099 Late-onset SLE in real-world practice: higher comorbidity burden with comparable clinical, serologic, and treatment profiles |